Loading clinical trials...

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGPHASE2/PHASE3

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

NCT03898479•Sun Pharmaceutical Industries, Inc.

View on ClinicalTrials.gov

Summary

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Have completed 24 weeks of treatment in a previous qualifying CTP-543 clinical trial

Exclusion Criteria

•Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or untreated actinic keratosis
•Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study medication
•Donation of blood at any point throughout the study and for 30 days after last dose of study medication

Locations (91)

Total Skin and Beauty Dermatology Center

Birmingham, Alabama, United States

Alliance Dermatology & MOHS Center

Phoenix, Arizona, United States

Center for Dermatology and Plastic Surgery/CCT Research

Scottsdale, Arizona, United States

Johnson Dermatology

Fort Smith, Arkansas, United States

Northwest Arkansas Clinical Trials Center, PLLC

Rogers, Arkansas, United States

Kern Research Inc.

Bakersfield, California, United States

Hope Clinical Research

Canoga Park, California, United States

California Dermatology & Clinical Research Institute

Encinitas, California, United States

University of California, Irvine

Irvine, California, United States

Dermatology Research Associates

Los Angeles, California, United States

Key Dates

Start Date

April 4, 2019

Primary Completion Date

May 1, 2027

Completion Date

June 1, 2027

Last Updated

October 22, 2025

Enrollment

1,000

ESTIMATED participants

Conditions

Alopecia Areata

Interventions

CTP-543

DRUG

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata

NCT06826196

Alopecia Areata (AA)

View study

RECRUITING

CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry

NCT06562270

Alopecia Areata

View study

RECRUITINGPHASE3

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 22, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

Inclusion Criteria

Exclusion Criteria

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata

CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

Combined Microneedling With Either 1% Lactic Acid Solution or Vitamin D3 or Triamcinolone Acetonide in The Treatment of Alopecia Areata

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata

A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.